The Australian antigen test detects SARS‑CoV‑2 proteins to quickly identify current COVID‑19 infection. It’s used for people with symptoms, close contacts and routine screening to spot likely infectious cases rapidly. Results are fast but less sensitive than PCR; a positive usually indicates active infection, while a negative may need repeat testing or PCR confirmation if symptoms continue or exposure risk is high.

The Australian Ag test is a rapid antigen (Ag) test for SARS‑CoV‑2 that detects viral proteins from a nasal or throat swab using a lateral‑flow immunoassay. It delivers quick results (about 15–30 minutes) but is less sensitive than PCR, especially with low viral loads. It’s useful for early symptomatic screening and outbreak control; positive or uncertain results may need PCR confirmation and local health advice.

A positive HBsAg (hepatitis B surface antigen) means hepatitis B virus is present in the blood, indicating an active infection—either acute or chronic. It signals potential infectiousness and requires further evaluation with tests (antibodies, viral load, liver function) and clinical follow-up. Vaccination won’t clear an existing infection; management depends on chronicity, liver status, and possible antiviral treatment to reduce liver damage and transmission.

The Australia antigen is another name for the hepatitis B surface antigen (HBsAg). It is a protein on the outer envelope of hepatitis B virus, used as a key marker for infection. Detection of HBsAg in blood indicates acute or chronic hepatitis B and is used for screening, diagnosis, and blood-donor testing; it’s also the antigen used in hepatitis B vaccines.

A positive antigen test detects viral proteins from a current infection, indicating the person likely has an active, contagious infection. It’s a rapid screening result; false negatives and occasional false positives can occur. A positive result typically prompts self-isolation and may be followed by confirmatory PCR testing or clinical assessment, especially in high‑risk individuals or when treatment decisions are needed.

VDRL stands for Venereal Disease Research Laboratory test. It’s a non-treponemal serological screening test that detects reagin antibodies produced in response to Treponema pallidum infection (syphilis). Positive results require confirmation with treponemal-specific tests. VDRL may yield false positives in other conditions and is also used to monitor treatment response by measuring antibody titre changes over time.